Document is current
Any future updates will be listed below
-
Authors
Chiapparelli, Erika https://orcid.org/0000-0001-9646-2397
Burkhard, Marco D. https://orcid.org/0000-0003-1501-1952
Amoroso, Krizia https://orcid.org/0009-0004-9703-262X
Guven, Ali E. https://orcid.org/0009-0004-7663-9043
Camino-Willhuber, Gaston https://orcid.org/0000-0002-5684-7679
Zhu, Jiaqi
Caffard, Thomas https://orcid.org/0000-0001-9468-2089
Evangelisti, Gisberto https://orcid.org/0000-0002-5185-4482
Hambrecht, Jan https://orcid.org/0009-0007-4152-7465
Köhli, Paul https://orcid.org/0000-0001-7473-6553
Tsuchiya, Koki https://orcid.org/0000-0001-9105-6939
Shue, Jennifer https://orcid.org/0000-0001-9885-3834
Sama, Andrew https://orcid.org/0000-0002-3014-7287
Girardi, Federico P. https://orcid.org/0000-0002-3269-7602
Cammisa, Frank P. https://orcid.org/0000-0002-5797-977X
Hughes, Alexander P. https://orcid.org/0000-0001-7293-9672
- License Information
-
More Information
Article History
Received: 11 March 2024
Revised: 11 March 2024
Accepted: 16 May 2024
First Online: 27 June 2024
Declarations
:
: The investigation follows the Declaration of Helsinki and was approved by the HSS Institutional Review Board (IRB) under the approval number IRB#2014-084. All patients provided their informed written consent before surgery. No drug or devices requiring FDA approval was discussed. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Dr. Sama reports royalties from Ortho Development, Corp. DePuy Spine Products/Medical Device Business Services, Clariance, Inc.; private investments for Vestia Ventures MiRUS Investment, LLC, ISPH II, LLC, ISPH 3, LLC, and Centinel Spine (Vbros Venture Partners V); consulting fees from DePuy Spine Products/Medical Device Business Services, Clariance, Inc., Kuros Biosciences AG; speaking and/or teaching arrangements for DePuy Spine Products/Medical Device Business Services; membership of scientific advisory board of DePuy Spine Products/Medical Device Business Services, Kuros Biosciences AG, Clariance, Inc., and research support from Spinal Kinetics, Inc./Orthofix, Inc., outside the submitted work. Dr. Cammisa reports royalties from Accelus; ownership interest for 4WEB Medical/4WEB, Inc.; Healthpoint Capital Partners, LP; ISPH II, LLC; ISPH 3 Holdings, LLC; Ivy Healthcare Capital Partners, LLC; Medical Device Partners II, LLC; Medical Device Partners III, LLC; Orthobond Corporation; Spine Biopharma, LLC; Tissue Differentiation Intelligence, LLC; Tissue Connect Systems, Inc.; VBVP VI, LLC; VBVP X, LLC; Woven Orthopedics Technologies; consulting fees from Spine Biopharma, LLC, and Accelus; membership of scientific advisory board/other office of Healthpoint Capital Partners, Medical Device Partners II, LLC, Orthobond Corporation, Spine Biopharma, LLC, and Woven Orthopedic Technologies; and research support from 4WEB Medical/4WEB, Inc., Camber Spine, Choice Spine, DePuy Synthes, Centinel Spine, and Royal Biologics outside the submitted work. Dr. Girardi reports royalties from Lanx, Inc. and Ortho Development Corp.; ownership interest in Centinel Spine, BICMD; consulting fees from Lanx, Inc,, Ortho Development Corp, and Sea Spine; and stock ownership in Centinel Spine, Healthpoint Capital Partners, LP; membership of scientific advisory board/other office of Healthpoint Capital Partners, outside the submitted work. Dr. Hughes reports research support from Kuros Biosciences AG and Expanding Innovations, Inc.; private investments in Tissue Connect Systems, Inc.; and fellowship support from NuVasive, Inc. outside the submitted work.
